Efficacy and Safety of Benmelstobart Plus Anlotinib in Advanced Endometrial Cancer: Results of a Multi-Cohort, Phase II Study (ETER200).

@article{liang2026efficacy,
  title = {{Efficacy and Safety of Benmelstobart Plus Anlotinib in Advanced Endometrial Cancer: Results of a Multi-Cohort, Phase II Study (ETER200).}},
  author = {Shanhui Liang and Xiaojun Chen and Ke Wang and Dong Wang and Ruifang An and Jianqing Hou and Ying Yang and Danbo Wang and Pengpeng Qu and Bingzhong Zhang and Wei Duan and Xiumin Li and Aimin Zang and Guohua Yu and Hanmei Lou and Desheng Yao and Shuzhen Wang and Dong Yan and Liang Li and Xiaowei Liu and Weidong Zhao and Zhengzheng Chen and Jing Fei and Jundong Li and Jing Wang and Zhilian Wang and Shuzhong Yao and Fangling Ning and Huaijun Zhou and Li Sun and Lingya Pan and Qing Liu and Haihua Yang and Li Wang and Mingjun Zhang and Xiaoxiang Chen and Jianlin Yuan and Xinwen Zhang and Youzhong Zhang and Qinping Liao and Xiaohua Wu},
  journal = {MedComm},
  year = {2026},
  month = oct,
  doi = {10.1002/mco2.71081},
  url = {https://europepmc.org/article/MED/42910366},
  note = {CC BY},
}

TY  - JOUR
TI  - Efficacy and Safety of Benmelstobart Plus Anlotinib in Advanced Endometrial Cancer: Results of a Multi-Cohort, Phase II Study (ETER200).
AU  - Shanhui Liang
AU  - Xiaojun Chen
AU  - Ke Wang
AU  - Dong Wang
AU  - Ruifang An
AU  - Jianqing Hou
AU  - Ying Yang
AU  - Danbo Wang
AU  - Pengpeng Qu
AU  - Bingzhong Zhang
AU  - Wei Duan
AU  - Xiumin Li
AU  - Aimin Zang
AU  - Guohua Yu
AU  - Hanmei Lou
AU  - Desheng Yao
AU  - Shuzhen Wang
AU  - Dong Yan
AU  - Liang Li
AU  - Xiaowei Liu
AU  - Weidong Zhao
AU  - Zhengzheng Chen
AU  - Jing Fei
AU  - Jundong Li
AU  - Jing Wang
AU  - Zhilian Wang
AU  - Shuzhong Yao
AU  - Fangling Ning
AU  - Huaijun Zhou
AU  - Li Sun
AU  - Lingya Pan
AU  - Qing Liu
AU  - Haihua Yang
AU  - Li Wang
AU  - Mingjun Zhang
AU  - Xiaoxiang Chen
AU  - Jianlin Yuan
AU  - Xinwen Zhang
AU  - Youzhong Zhang
AU  - Qinping Liao
AU  - Xiaohua Wu
PY  - 2026
DA  - 2026/10/21
JO  - MedComm
DO  - 10.1002/mco2.71081
UR  - https://europepmc.org/article/MED/42910366
AB  - Patients with advanced endometrial cancer (EC) have a poor prognosis and limited therapeutic options after failure of prior systemic therapy. In this multi-cohort Phase II study (ETER200), patients with metastatic or recurrent EC who had received at least one chemotherapy regimen were enrolled. Based on MSI/MMR status, patients received benmelstobart plus anlotinib (Cohort 1), benmelstobart (Cohort 2), or anlotinib (Cohort 3) every 3 weeks. Primary endpoint was objective response rate (ORR) assessed by independent review committee (IRC) per RECIST v1.1. Here, the results of Cohort 1 expansion stage were reported. As of May 9, 2024, 85 of the 107 non-MSI-H/pMMR EC patients enrolled in Cohort 1 constituted the expansion stage population for primary efficacy analysis. The IRC-assessed ORR was 34.1% (95% CI, 24.2-45.2), with a median duration of response of 15.2 months (95% CI, 6.9-not evaluable). Median progression-free and overall survival were 8.8 months (95% CI, 5.8-15.2) and 21.8 months (95% CI, 19.5-29.1), respectively. Grade ≥ 3 treatment-related adverse events occurred in 69.2% of patients, most commonly hypertension (21.2%) and palmar-plantar erythrodysesthesia syndrome (9.4%). Overall, benmelstobart plus anlotinib showed promising anti-tumor activity and an acceptable safety profile in advanced non-MSI-H/pMMR EC, supporting further evaluation of this combination in randomized Phase III studies. Trial Registration: ClinicalTrials.gov, NCT04574284.
SN  - 2688-2663
ER  -